Clinical efficacy of pemetrexed disodium in maintenance treatment of advanced lung adenocarcinoma
10.3760/cma.j.cn341190-20220109-00021
- VernacularTitle:培美曲塞二钠在晚期肺腺癌患者同药维持治疗中的临床疗效
- Author:
Juan NING
1
;
Lijuan HU
;
Xiaoyan WANG
;
Hao GONG
Author Information
1. 北京市海淀医院肿瘤血液内科，北京 100080
- Keywords:
Adenocarcinoma, bronchiolo-alveolar;
Folic acid antagonists;
Maintenance Chemotherapy;
Drug-Related side effects and adverse reactions;
Quality of life;
Sa
- From:
Chinese Journal of Primary Medicine and Pharmacy
2023;30(1):39-43
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy and adverse reactions of pemetrexed disodium in the maintenance treatment of advanced lung adenocarcinoma after chemotherapy with pemetrexed disodium and platinum.Methods:The clinical data of 35 patients with stage Ⅳ lung adenocarcinoma who received chemotherapy with pemetrexed disodium and platinum and were well treated in Beijing Huairou Hospital from January 2013 to August 2020 were retrospectively analyzed. Maintenance therapy with pemetrexed disodium was initiated after the completion of combination chemotherapy until disease progression. The clinical characteristics, therapeutic effects, adverse reactions, progression-free survival, and overall survival of the 35 patients were evaluated.Results:Among the 35 patients, no patients had complete remission, 11 patients had partial remission, 22 patients had stable disease, and 2 patients had progressive disease. The objective remission rate was 31.4%, disease control rate was 94.3%, median progression-free survival was 9.53 months, median overall survival was 18.21 months, 1-year survival rate was 68.6%, 2-year survival rate was 31.4%, and 3-year survival rate was 11.4%. Gender, age, smoking, and the baseline characteristics of patients undergoing first-line pemetrexed disodium or second-line pemetrexed disodium treatment had no effects on progression-free survival (all P > 0.05). Positive gene mutation and receiving four or more chemotherapy cycles had a protective effect on progression-free survival (both P < 0.05). Chemotherapy-related adverse reactions mainly included myelosuppression, nausea, elevated transaminase, and nephrotoxicity, all of which were mild and were relieved after symptomatic treatment. Conclusion:Pemetrexed disodium is effective and safe in the maintenance treatment of advanced lung adenocarcinoma. The results of this study are scientific.
